M Youle

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Joseph J. Eron, Benjamin Young, David A. Cooper et al. · The Lancet · 2010 · 312 citations

Switchmrk 1, Treatment And Prevention, Human Retrovirus +10

Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre

Amanda Mocroft, M Youle, Antonia L. Moore et al. · AIDS · 2001 · 229 citations

Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.

Amanda Mocroft, M Youle, Brian Gazzard et al. · PubMed · 1996 · 154 citations

Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing

Anne–Mieke Vandamme, Anders Sönnerborg, Mounir Ait‐Khaled et al. · Antiviral Therapy · 2004 · 144 citations · Full text

Pharmacotherapy, Resistance Testing, Clinical Use +17

Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.

M Youle, J. Clarbour, Charles Farthing et al. · BMJ · 1989 · 141 citations · Full text

Vascular Disease, Vasculitis, Vascular Malformation +17